Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemiaDEININGER, Michael W. N.Journal of cancer research and clinical oncology. 2004, Vol 130, Num 2, pp 59-72, issn 0171-5216, 14 p.Article

Selection of Therapy: Rational Decisions Based on Molecular EventsKHORASHAD, Jamshid S; DEININGER, Michael W. N.Hematology/oncology clinics of North America. 2011, Vol 25, Num 5, issn 0889-8588, 1009-1023, vi [16 p.]Article

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaO'HARE, Thomas; EIDE, Christopher A; DEININGER, Michael W. N et al.Blood. 2007, Vol 110, Num 7, pp 2242-2249, issn 0006-4971, 8 p.Article

The molecular biology of chronic myeloid leukemiaDEININGER, Michael W. N; GOLDMAN, John M; MELO, Junia V et al.Blood. 2000, Vol 96, Num 10, pp 3343-3356, issn 0006-4971Article

Cytogenetic studies in patients on imatinibDEININGER, Michael W. N.Seminars in hematology. 2003, Vol 40, Num 2, pp 50-55, issn 0037-1963, 6 p., SUP2Conference Paper

Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformationMELO, Junia V; DEININGER, Michael W. N.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, pp vii-viii, issn 0889-8588, 26 p.Article

Practical management of patients with chronic myeloid leukemia receiving imatinibDEININGER, Michael W. N; O'BRIEN, Stephen G; FORD, John M et al.Journal of clinical oncology. 2003, Vol 21, Num 8, pp 1637-1647, issn 0732-183X, 11 p.Article

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive LeukemiaO'HARE, Thomas; DEININGER, Michael W. N; EIDE, Christopher A et al.Clinical cancer research (Print). 2011, Vol 17, Num 2, pp 212-221, issn 1078-0432, 10 p.Article

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsTYNER, Jeffrey W; ERICKSON, Heidi; LORIAUX, Marc M et al.Blood. 2009, Vol 113, Num 8, pp 1749-1755, issn 0006-4971, 7 p.Article

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignanciesSCHITTENHELM, Marcus M; SHIRAGA, Sharon; SCHROEDER, Arin et al.Cancer research (Baltimore). 2006, Vol 66, Num 1, pp 473-481, issn 0008-5472, 9 p.Article

Characterization of murine JAK2^V617F-positive myeloproliferative diseaseBUMM, Thomas G. P; ELSEA, Collin; CORBIN, Amie S et al.Cancer research (Baltimore). 2006, Vol 66, Num 23, pp 11156-11165, issn 0008-5472, 10 p.Article

Emergence of clonal cytogenetic abnormalities in Ph^- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majorityBUMM, Thomas; MÜLLER, Christel; KRAHL, Reiner et al.Blood. 2003, Vol 101, Num 5, pp 1941-1949, issn 0006-4971, 9 p.Article

The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABL^T3151 and Exhibits a Narrow Resistance ProfileEIDE, Christopher A; ADRIAN, Lauren T; O'HARE, Thomas et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 9, pp 3189-3195, issn 0008-5472, 7 p.Article

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of KitCORBIN, Amie S; DEMEHRI, Shadmehr; LULIUCCI, John et al.Blood. 2005, Vol 106, Num 1, pp 227-234, issn 0006-4971, 8 p.Article

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaLEVINE, Ross L; LORIAUX, Marc; FLORES, Nikki J et al.Blood. 2005, Vol 106, Num 10, pp 3377-3379, issn 0006-4971, 3 p.Article

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970CORBIN, Amie S; GRISWOLD, Ian J; LA ROSEE, Paul et al.Blood. 2004, Vol 104, Num 12, pp 3754-3757, issn 0006-4971, 4 p.Article

A Specific Need for CRKL in p210^BCR-ABL―Induced Transformation of Mouse Hematopoietic ProgenitorsSEO, Ji-Heui; WOOD, Lisa J; AGARWAL, Anupriya et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 18, pp 7325-7335, issn 0008-5472, 11 p.Article

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinibPRESS, Richard D; WILLIS, Stephanie G; LAUDADIO, Jennifer et al.Blood. 2009, Vol 114, Num 13, pp 2598-2605, issn 0006-4971, 8 p.Article

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsO'HARE, Thomas; WALTERS, Denise K; DRUKER, Brian J et al.Cancer research (Baltimore). 2005, Vol 65, Num 11, pp 4500-4505, issn 0008-5472, 6 p.Article

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesisGRISWOLD, Ian J; SHEN, Lei J; DEININGER, Michael W. N et al.Blood. 2004, Vol 104, Num 9, pp 2912-2918, issn 0006-4971, 7 p.Article

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletionsHUNTLY, Brian J. P; GUILHOT, Francois; CUTHBERT, Gavin et al.Blood. 2003, Vol 102, Num 6, pp 2205-2212, issn 0006-4971, 8 p.Article

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 studySHAH, Neil P; TALPAZ, Moshe; HALUSKA, Frank G et al.British journal of haematology. 2013, Vol 162, Num 4, pp 548-552, issn 0007-1048, 5 p.Article

Ponatinib in Refractory Philadelphia Chromosome: Positive LeukemiasCORTES, Jorge E; KANTARJIAN, Hagop; CLACKSON, Tim et al.The New England journal of medicine. 2012, Vol 367, Num 22, pp 2075-2088, issn 0028-4793, 14 p.Article

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinibO'HARE, Thomas; WALTERS, Denise K; STOFFREGEN, Eric P et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 6987-6993, issn 1078-0432, 7 p., 1Article

In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signaturesCROSSMAN, Lucy C; MORI, Motomi; DRUKER, Brian J et al.Haematologica (Roma). 2005, Vol 90, Num 4, pp 459-464, issn 0390-6078, 6 p.Article